all he talked about was the current test platform. Nothing about any of the new tests coming out shortly. pretty shallow analysis imho.
what mygn needs is a buyout by someone like JNJ that has a covey of attorneys to fight the patent infringements as a routine course of biz.
No one will buy this company. They have one product that just lost patent protection and they're hanging on for dear life trying to sue everyone and trying to make wallstreet believe they still have patent claims. Everyone, including Myriad knows the rest of their claims are bogus.
I'm going to ask a meaningful, non-rhetorical question" Why don't YOU offer BRCA testing? There are, of course, lots of reasons, and a remarkably large number of them apply even to established medical testing companies.
You've persisted in using small molecule drugs that lose patent protection as a model. Consider instead advanced biologics that lose patent protection--generics have a much harder slog because full equivalence is impossible, and practical equivalence is hard to sell.
first, they don't have one product
second, that product is and will continue to produce very strong free cash flows
third, I heard the same argument with Questcor 3 months ago and all that stock did is triple
fourth, they have over $500MM in cash and no debt
fifth, their research team is first class including a Nobel prize winner